TG Therapeutics, Inc.

TGTX Healthcare Biotechnology

TG Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $616.3 million, up 87.3% from fiscal 2024. In the quarter to June 2026, revenue grew 70.3%, EPS fell 73.7%, free cash flow grew 427.1% and total debt rose 204.2%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

53.97 2.03 −3.63%
Market cap
$8.6B
P/E
17.8×
Fwd P/E
29.4×
Dividend yield
—
F-score
5/9
Altman Z
6.29
Beneish M
0.80
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Total current assets
50.86 93.32 79.03 149.15 611.74 330.97 168.27 317.94 566.36 630.76
Total non-current assets
3.92 4.06 4.59 13.86 13.90 48.66 25.30 11.64 11.33 432.49
Total Assets
54.78 97.38 83.62 163.01 625.64 379.63 193.57 329.59 577.69 1,063.25
Total current liabilities
16.88 27.96 38.85 84.45 87.55 65.38 53.20 53.72 90.68 153.76
Total non-current liabilities
2.04 2.43 20.73 39.95 18.74 77.09 81.78 115.37 264.65 261.47
Total liabilities
18.91 30.39 59.58 124.40 106.29 142.48 134.99 169.09 355.33 415.23
Common Equity (Total)
35.87 66.99 24.04 38.62 519.35 237.15 58.59 160.50 222.36 648.02
Shareholders Equity (Total)
35.87 66.99 24.04 38.62 519.35 237.15 58.59 160.50 222.36 648.02
Total Debt
0.07 0.13 0.07 30.78 32.50 67.76 71.14 100.12 244.43 245.65

Show all line items

In millions of $ except per-share values · columns are period end dates